Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report

키워드

참고문헌 (21)

1. Ajnakina O, "Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia", Schizophr Res, 197, pp.294~297 (2018)
2. "Psychosis and schizophrenia in adults: prevention and management" (2014)[URL]
3. Kane J, "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine", Arch Gen Psychiatry, 45, pp.789~796 (1988)
4. Meltzer HY, "Clozapine : balancing safety with superior antipsychotic efficacy", Clin Schizophr Relat Psychoses, 6, pp.134~144 (2012)
5. Ahmed S, "Combined use of electroconvulsive therapy and antipsychotics(both clozapine and non-clozapine)in treatment resistant schizophrenia : a comparative meta-analysis", Heliyon, 3, pp.e00429~ (2017)
6. Shahid M, "Asenapine : a novel psychopharmacologic agent with a unique human receptor signature", J Psychopharmacol, 23, pp.65~73 (2009)
7. Meltzer HY, "The role of serotonin receptors in the action of atypical antipsychotic drugs", Curr Opin Pharmacol, 11, pp.59~67 (2011)
8. Potkin SG, "Efficacy and tolerability of asenapine in acute schizophrenia : a placebo-and risperidone-controlled trial", J Clin Psychiatry, 68, pp.1492~1500 (2007)
9. Kane JM, "A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment", J Clin Psychiatry, 72, pp.349~355 (2011)
10. Buoli M, "Augmentative asenapine in a recurrent manic catatonic patient with partial response to clozapine", Case Rep Psychiatry, 2013, pp.503601~ (2013)
11. Smith EN, "Asenapine augmentation and treatment-resistant schizophrenia in the high-secure hospital setting", Ther Adv Psychopharmacol, 4, pp.193~197 (2014)
12. Kay SR, "The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation", Br J Psychiatry Suppl, (7), pp.59~67 (1989)
13. Abdullah Bolu, "Low-dose Clozapine-induced Seizure: A Case Report", Clinical Psychopharmacology and Neuroscience, 15(2), pp.190~193 (2017), 대한정신약물학회[DOI]
14. Grover S, "Effectiveness of electroconvulsive therapy in patients with treatment resistant schizophrenia : a retrospective study", Psychiatry Res, 249, pp.349~353 (2017)
15. Potkin SG, "Asenapine : a clinical overview", J Clin Psychiatry, 72(Suppl 1), pp.14~18 (2011)
16. Kusumi I, "Psychopharmacology of atypical antipsychotic drugs : from the receptor binding profile to neuroprotection and neurogenesis", Psychiatry Clin Neurosci, 69, pp.243~258 (2015)
17. Kishi T, "Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists : a meta-analysis", Int J Neuropsychopharmacol, 16, pp.1259~1266 (2013)
18. Morozova M, "5-HT6 receptor antagonist as an adjunct treatment targeting residual symptoms in patients with schizophrenia : unexpected sex-related effects(double-blind placebo-controlled trial)", J Clin Psychopharmacol, 37, pp.169~175 (2017)
19. Nikiforuk A, "Targeting the serotonin 5-HT7 receptor in the search for treatments for CNS disorders : rationale and progress to date", CNS Drugs, 29, pp.265~275 (2015)
20. Takekita Y, "Serotonin 7 receptor variants are not associated with response to second-generation antipsychotics in Japanese schizophrenia patients", Neuropsychobiology, 72, pp.118~125 (2015)
21. Pompili M, "Do atypical antipsychotics have antisuicidal effects? A hypothesis-generating overview", Int J Mol Sci, 17, pp.1700~ (2016)

관련 논문AI추천